In addition, BL-7010 will be presented at the Digestive
Disease Week 2013 conference, the world's largest gathering of
physicians and researchers in the fields of gastroenterology,
hepatology, endoscopy and gastrointestinal surgery, to be held on
BL-7010 is a novel, non-absorbable, orally available polymer intended
for the treatment of celiac disease and gluten sensitivity. It has a
high affinity for gliadins, the immunogenic peptides present in gluten
that cause celiac disease. By sequestering gliadins, BL-7010 effectively
masks them from enzymatic degradation and prevents the formation of
immunogenic peptides, which trigger the immune system in the digestive
tract. The BL-7010-gliadin complex is eventually excreted from the
digestive tract and is not absorbed into the blood. This significantly
reduces the immune response triggered by gluten. The safety and efficacy
of BL-7010 was demonstrated in pre-clinical studies. BL-7010 was
invented by Prof.
About Celiac Disease and Gluten Sensitivity
Celiac disease is a chronic, autoimmune, inflammatory disease of the small intestine characterized by damage to the lining of the small intestine and typically leads to dyspepsia, malabsorption and a variety of other symptoms. It occurs in genetically predisposed individuals and is caused by an immunological reaction to gluten, found in wheat, barley and rye. Estimates suggest that 1% of the world’s population is affected by celiac disease, and prevalence is expected to increase dramatically with improved diagnosis and awareness of the disease. Today there are no pharmacological agents approved for celiac disease and the only treatment option is a life-long, strict, gluten-free diet, which is difficult to maintain both due to food contamination with gluten, as well as eating habits in a social setting. Non-celiac gluten sensitivity is a common name for cases of gluten reactions in which neither allergic nor autoimmune mechanisms are involved or can be identified.
BioLineRx is a publicly-traded biopharmaceutical development company.
BioLineRx is dedicated to building a portfolio of products for unmet
medical needs or with advantages over currently available therapies.
BioLineRx’s current portfolio consists of seven clinical stage
candidates: BL-1040, for prevention of pathological cardiac remodeling
following a myocardial infarction, which has been out-licensed to
BioLineRx’s business model is based on acquiring molecules mainly from
biotechnological incubators and academic institutions. The Company
performs feasibility assessment studies and development through
pre-clinical and clinical stages, with partial funding from the Israeli